PulseSight is pioneering a unique non-viral gene therapy approach, combining novel plasmid-encoded therapeutic proteins with a proprietary electro-transfection delivery technology.1
PulseSight’s platform delivers plasmids encoding therapeutic proteins into the ciliary muscle using a proprietary electro-transfection device.
The administration system consists of a dedicated ocular device associated to a pulse generator delivering controlled electrical pulses that transiently increase cell membrane permeability, enabling plasmid penetration in the ciliary muscle cells. Once transfected, these cells act as a biofactory, producing therapeutic proteins that distribute into the vitreous and the retina in a sustained manner.
PulseSight’s non viral gene therapy technology provides significant advantages for the treatment of severe eye diseases:
- No cargo-size limitation, enabling the delivery of a broad range of therapeutic proteins.
- Sustained intraocular protein expression, reducing the need for frequent reinjections.
- Preclinical data demonstrate protein expression for up to six months following administration of PST-611.
- Favourable safety profile, demonstrated in both preclinical and clinical studies.
- Same administration procedure and device, applicable across all drug candidates.
1Touchard et al. The ciliary smooth muscle electrotransfer: basic principles and potential for sustained intraocular production of therapeutic proteins. J Gene Med 12(11):904-19 (2010)